Arine vs FeelBetter (2026)
Both find the patients whose medication list has become the problem, and they sell that to different buyers. Arine sells medication intelligence to health plans, working across a membership and reporting savings per engaged member, and its platform holds HITRUST r2, the program's most demanding tier. FeelBetter targets polypharmacy in older adults, placing each patient in one of 22 risk levels, and a peer reviewed evaluation it cites names the data its model uses. That study measured something narrower than the company's marketing claims. If you are a plan, Arine is built for your data and your contracting. If you are a provider group or a pharmacy service managing complex older patients, FeelBetter is aimed at the clinical problem rather than the medical loss ratio.
- The buyer and the workflow are on the payer side, ingesting clinical, socioeconomic and behavioral data across a plan's membership to find members at risk before an event.
- HITRUST r2 certification, attained in 2024, covers the Arine platform, and r2 is the program's most demanding tier.
- Results are named to real clients with quantified savings per engaged member, even though the figures are self reported.
- The population is the sharper target: older adults on enough medications that the regimen itself is the hazard, stratified by risk of near term deterioration or hospitalization.
- A peer reviewed evaluation in the American Journal of Managed Care names the model's inputs and risk levels, and a buyer can read what it did and did not measure.
- Recommendations reach a clinical pharmacist, and any change still requires a prescriber.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Arine and FeelBetter are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Arine | FeelBetter |
|---|---|---|
| Primary category | Medication Safety & Prescribing | Medication Safety & Prescribing |
| Founded | 2019 | 2018 |
| Headquarters | San Francisco, California, United States | Boston, Massachusetts, United States and Tel Aviv, Israel |
| Website | arine.io | feelbetter.healthcare |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Arine sells medication intelligence to health plans rather than to hospitals. The platform ingests clinical, socioeconomic and behavioral data across a plan's membership, identifies members at risk of medication related problems before they produce an event, generates personalized care plans for clinical pharmacists to act on, and separately analyses prescriber behavior so a plan can direct education and recommendations at the clinicians writing the prescriptions.
Source: AI Health Index, September 2026
FeelBetter applies machine learning to polypharmacy, the problem of an older patient accumulating enough medications that the regimen itself becomes the hazard. The platform synthesizes longitudinal pharmacy and clinical data across a whole population, identifies the patients at highest risk of near term deterioration or hospitalization attributable to their medication regimen, recommends specific regimen changes to a clinical pharmacist, and monitors what happens after the intervention.
Source: AI Health Index, September 2026
Questions buyers ask
How are Arine and FeelBetter priced and sold?
The site promises guaranteed outcomes and immediate return on investment and expresses its results per engaged member per year, a unit that answers the value question and leaves the cost question untouched; nothing says whether Arine charges per member, per engaged member, per program or on an outcome linked basis, or what the guarantee commits it to.
With FeelBetter, the company's own site lists its impact metrics as labeled categories, savings per high risk patient per month and average review time per complex patient, with one carrying a figure and the other left as a heading, so even the return side is only partly quantified while the cost side is entirely absent. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 20, 2026. No vendor pays for placement.
Which settings and specialties do Arine and FeelBetter cover?
In Arine's case, the product is exclusively payer side with no provider or health system deployment described, coverage is United States only and tied to American program structures such as Part D measures, and the member populations skew heavily to government sponsored programs.
For FeelBetter, the population is consistent throughout, older adults with multiple chronic conditions and complex regimens, which is the group where polypharmacy causes the most harm and where the intervention has the clearest value. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 20, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Both vendors sell outcomes measured by the party being paid for them. Arine's savings figures per engaged member are self reported, and FeelBetter presents impact metrics as labeled categories rather than as a study, so ask both for the denominator, the comparison group and who computed the result. Neither states a HIPAA status or publishes business associate terms. FeelBetter publishes no security attestation or trust center. Neither publishes results by patient group or a bias assessment, a wide gap for products stratifying an older population. Neither publishes a price.